T cells are key components in environments that support chronic lymphocytic leukemia (CLL), activating CLL-cell proliferation and survival. Here, we review in vitro and in vivo model systems that mimic CLL-T-cell interactions, since these are critical for CLL-cell division and resistance to some types of therapy (such as DNA-damaging drugs or BH3-mimetic venetoclax). We discuss approaches for direct CLL-cell co-culture with autologous T cells, models utilizing supportive cell lines engineered to express T-cell factors (such as CD40L) or stimulating CLL cells with combinations of recombinant factors (CD40L, interleukins IL4 or IL21, INFγ) and additional B-cell receptor (BCR) activation with anti-IgM antibody. We also summarize strategies for CLL co-transplantation with autologous T cells into immunodeficient mice (NOD/SCID, NSG, NOG) to generate patient-derived xenografts (PDX) and the role of T cells in transgenic CLL mouse models based on TCL1 overexpression (Eµ-TCL1). We further discuss how these in vitro and in vivo models could be used to test drugs to uncover the effects of targeted therapies (such as inhibitors of BTK, PI3K, SYK, AKT, MEK, CDKs, BCL2, and proteasome) or chemotherapy (fludarabine and bendamustine) on CLL-T-cell interactions and CLL proliferation.

Department of Internal Medicine Hematology and Oncology University Hospital Brno and Faculty of Medicine Masaryk University 62500 Brno Czech Republic

Faculty of Science Masaryk University 61137 Brno Czech Republic

Molecular Medicine CEITEC Masaryk University 62500 Brno Czech Republic

Zobrazit více v PubMed

Smit L.A., Hallaert D.Y.H., Spijker R., de Goeij B., Jaspers A., Kater A.P., van Oers M.H.J., van Noesel C.J.M., Eldering E. Differential Noxa/Mcl-1 Balance in Peripheral versus Lymph Node Chronic Lymphocytic Leukemia Cells Correlates with Survival Capacity. Blood. 2007;109:1660–1668. doi: 10.1182/blood-2006-05-021683. PubMed DOI

Herndon T.M., Chen S.-S., Saba N.S., Valdez J., Emson C., Gatmaitan M., Tian X., Hughes T.E., Sun C., Arthur D.C., et al. Direct In Vivo Evidence for Increased Proliferation of CLL Cells in Lymph Nodes Compared to Bone Marrow and Peripheral Blood. Leukemia. 2017;31:1340–1347. doi: 10.1038/leu.2017.11. PubMed DOI PMC

Herishanu Y., Pérez-Galán P., Liu D., Biancotto A., Pittaluga S., Vire B., Gibellini F., Njuguna N., Lee E., Stennett L., et al. The Lymph Node Microenvironment Promotes B-Cell Receptor Signaling, NF-ΚB Activation, and Tumor Proliferation in Chronic Lymphocytic Leukemia. Blood. 2011;117:563–574. doi: 10.1182/blood-2010-05-284984. PubMed DOI PMC

Pavlasova G., Borsky M., Svobodova V., Oppelt J., Cerna K., Novotna J., Seda V., Fojtova M., Fajkus J., Brychtova Y., et al. Rituximab Primarily Targets an Intra-Clonal BCR Signaling Proficient CLL Subpopulation Characterized by High CD20 Levels. Leukemia. 2018;32:2028–2031. doi: 10.1038/s41375-018-0211-0. PubMed DOI

Seda V., Mraz M. B-Cell Receptor Signalling and Its Crosstalk with Other Pathways in Normal and Malignant Cells. Eur. J. Haematol. 2015;94:193–205. doi: 10.1111/ejh.12427. PubMed DOI

Haselager M.V., Kater A.P., Eldering E. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing? Front. Oncol. 2020;10:2205. doi: 10.3389/fonc.2020.592205. PubMed DOI PMC

Vlachonikola E., Stamatopoulos K., Chatzidimitriou A. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. Front. Immunol. 2021;11:612244. doi: 10.3389/fimmu.2020.612244. PubMed DOI PMC

Roessner P.M., Seiffert M. T-Cells in Chronic Lymphocytic Leukemia: Guardians or Drivers of Disease? Leukemia. 2020;34:2012–2024. doi: 10.1038/s41375-020-0873-2. PubMed DOI PMC

Wu X., Fajardo-Despaigne J.E., Zhang C., Neppalli V., Banerji V., Johnston J.B., Gibson S.B., Marshall A.J. Altered T Follicular Helper Cell Subsets and Function in Chronic Lymphocytic Leukemia. Front. Oncol. 2021;11:674492. doi: 10.3389/fonc.2021.674492. PubMed DOI PMC

Ponzoni M., Doglioni C., Caligaris-Cappio F. Chronic Lymphocytic Leukemia: The Pathologist’s View of Lymph Node Microenvironment. Semin. Diagn. Pathol. 2011;28:161–166. doi: 10.1053/j.semdp.2011.02.014. PubMed DOI

Ahearne M.J., Willimott S., Piñon L., Kennedy D.B., Miall F., Dyer M.J.S., Wagner S.D. Enhancement of CD154/IL4 Proliferation by the T Follicular Helper (Tfh) Cytokine, IL21 and Increased Numbers of Circulating Cells Resembling Tfh Cells in Chronic Lymphocytic Leukaemia. Br. J. Haematol. 2013;162:360–370. doi: 10.1111/bjh.12401. PubMed DOI

Coscia M., Pantaleoni F., Riganti C., Vitale C., Rigoni M., Peola S., Castella B., Foglietta M., Griggio V., Drandi D., et al. IGHV Unmutated CLL B Cells Are More Prone to Spontaneous Apoptosis and Subject to Environmental Prosurvival Signals than Mutated CLL B Cells. Leukemia. 2011;25:828–837. doi: 10.1038/leu.2011.12. PubMed DOI

Schattner E.J., Mascarenhas J., Reyfman I., Koshy M., Woo C., Friedman S.M., Crow M.K. Chronic Lymphocytic Leukemia B Cells Can Express CD40 Ligand and Demonstrate T-Cell Type Costimulatory Capacity. Blood. 1998;91:2689–2697. doi: 10.1182/blood.V91.8.2689.2689_2689_2697. PubMed DOI

Gonzalez-Rodriguez A.P., Contesti J., Huergo-Zapico L., Lopez-Soto A., Fernández-Guizán A., Acebes-Huerta A., Gonzalez-Huerta A.J., Gonzalez E., Fernandez-Alvarez C., Gonzalez S. Prognostic Significance of CD8 and CD4 T Cells in Chronic Lymphocytic Leukemia. Leuk. Lymphoma. 2010;51:1829–1836. doi: 10.3109/10428194.2010.503820. PubMed DOI

Long M., Beckwith K., Do P., Mundy B.L., Gordon A., Lehman A.M., Maddocks K.J., Cheney C., Jones J.A., Flynn J.M., et al. Ibrutinib Treatment Improves T Cell Number and Function in CLL Patients. J. Clin. Investig. 2017;127:3052–3064. doi: 10.1172/JCI89756. PubMed DOI PMC

Davis J.E., Sharpe C., Mason K., Tam C.S., Koldej R.M., Ritchie D.S. Ibrutinib Protects T Cells in Patients with CLL from Proliferation-Induced Senescence. J. Transl. Med. 2021;19:473. doi: 10.1186/s12967-021-03136-2. PubMed DOI PMC

Görgün G., Holderried T.A.W., Zahrieh D., Neuberg D., Gribben J.G. Chronic Lymphocytic Leukemia Cells Induce Changes in Gene Expression of CD4 and CD8 T Cells. J. Clin. Investig. 2005;115:1797–1805. doi: 10.1172/JCI24176. PubMed DOI PMC

Tötterman T.H., Carlsson M., Simonsson B., Bengtsson M., Nilsson K. T-Cell Activation and Subset Patterns Are Altered in B-CLL and Correlate with the Stage of the Disease. Blood. 1989;74:786–792. doi: 10.1182/blood.V74.2.786.786. PubMed DOI

Vardi A., Vlachonikola E., Karypidou M., Stalika E., Bikos V., Gemenetzi K., Maramis C., Siorenta A., Anagnostopoulos A., Pospisilova S., et al. Restrictions in the T-Cell Repertoire of Chronic Lymphocytic Leukemia: High-Throughput Immunoprofiling Supports Selection by Shared Antigenic Elements. Leukemia. 2017;31:1555–1561. doi: 10.1038/leu.2016.362. PubMed DOI

Riches J.C., Davies J.K., McClanahan F., Fatah R., Iqbal S., Agrawal S., Ramsay A.G., Gribben J.G. T Cells from CLL Patients Exhibit Features of T-Cell Exhaustion but Retain Capacity for Cytokine Production. Blood. 2013;121:1612–1621. doi: 10.1182/blood-2012-09-457531. PubMed DOI PMC

Kitada S., Zapata J.M., Andreeff M., Reed J.C. Bryostatin and CD40-Ligand Enhance Apoptosis Resistance and Induce Expression of Cell Survival Genes in B-Cell Chronic Lymphocytic Leukaemia. Br. J. Haematol. 1999;106:995–1004. doi: 10.1046/j.1365-2141.1999.01642.x. PubMed DOI

Os A., Bürgler S., Ribes A.P., Funderud A., Wang D., Thompson K.M., Tjønnfjord G.E., Bogen B., Munthe L.A. Chronic Lymphocytic Leukemia Cells Are Activated and Proliferate in Response to Specific T Helper Cells. Cell Rep. 2013;4:566–577. doi: 10.1016/j.celrep.2013.07.011. PubMed DOI

Kater A.P., Dicker F., Mangiola M., Welsh K., Houghten R., Ostresh J., Nefzi A., Reed J.C., Pinilla C., Kipps T.J. Inhibitors of XIAP Sensitize CD40-Activated Chronic Lymphocytic Leukemia Cells to CD95-Mediated Apoptosis. Blood. 2005;106:1742–1748. doi: 10.1182/blood-2005-02-0695. PubMed DOI PMC

Dicker F., Kater A.P., Prada C.E., Fukuda T., Castro J.E., Sun G., Wang J.Y., Kipps T.J. CD154 Induces P73 to Overcome the Resistance to Apoptosis of Chronic Lymphocytic Leukemia Cells Lacking Functional P53. Blood. 2006;108:3450–3457. doi: 10.1182/blood-2006-04-017749. PubMed DOI PMC

Van Attekum M.H., Eldering E., Kater A.P. Chronic Lymphocytic Leukemia Cells Are Active Participants in Microenvironmental Cross-Talk. Haematologica. 2017;102:1469–1476. doi: 10.3324/haematol.2016.142679. PubMed DOI PMC

Burger J.A., Quiroga M.P., Hartmann E., Bürkle A., Wierda W.G., Keating M.J., Rosenwald A. High-Level Expression of the T-Cell Chemokines CCL3 and CCL4 by Chronic Lymphocytic Leukemia B Cells in Nurselike Cell Cocultures and after BCR Stimulation. Blood. 2009;113:3050–3058. doi: 10.1182/blood-2008-07-170415. PubMed DOI PMC

Hartmann E.M., Rudelius M., Burger J.A., Rosenwald A. CCL3 Chemokine Expression by Chronic Lymphocytic Leukemia Cells Orchestrates the Composition of the Microenvironment in Lymph Node Infiltrates. Leuk. Lymphoma. 2016;57:563–571. doi: 10.3109/10428194.2015.1068308. PubMed DOI PMC

Man S., Henley P. Chronic Lymphocytic Leukaemia: The Role of T Cells in a B Cell Disease. Br. J. Haematol. 2019;186:220–233. doi: 10.1111/bjh.15918. PubMed DOI

Vaca A.M., Ioannou N., Sivina M., Vlachonikola E., Clise-Dwyer K., Kim E., Li D., Ma Q., Ferrajoli A., Estrov Z., et al. Activation and Expansion of T-Follicular Helper Cells in Chronic Lymphocytic Leukemia Nurselike Cell Co-Cultures. Leukemia. 2022;36:1324–1335. doi: 10.1038/s41375-022-01519-y. PubMed DOI

Burgess M., Cheung C., Chambers L., Ravindranath K., Minhas G., Knop L., Mollee P., McMillan N.A.J., Gill D. CCL2 and CXCL2 Enhance Survival of Primary Chronic Lymphocytic Leukemia Cells in Vitro. Leuk. Lymphoma. 2012;53:1988–1998. doi: 10.3109/10428194.2012.672735. PubMed DOI

Calissano C., Damle R.N., Marsilio S., Yan X.-J., Yancopoulos S., Hayes G., Emson C., Murphy E.J., Hellerstein M.K., Sison C., et al. Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells. Mol. Med. 2011;17:1374–1382. doi: 10.2119/molmed.2011.00360. PubMed DOI PMC

Seda V., Vojackova E., Ondrisova L., Kostalova L., Sharma S., Loja T., Mladonicka Pavlasova G., Zicha D., Kudlickova Peskova M., Krivanek J., et al. FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia. Blood. 2021;138:758–772. doi: 10.1182/blood.2020008101. PubMed DOI PMC

Sharma S., Pavlasova G.M., Seda V., Cerna K.A., Vojackova E., Filip D., Ondrisova L., Sandova V., Kostalova L., Zeni P.F., et al. MiR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: An Axis Affected by BCR Inhibitors. Blood. 2021;137:2481–2494. doi: 10.1182/blood.2020005627. PubMed DOI PMC

Purroy N., Abrisqueta P., Carabia J., Carpio C., Palacio C., Bosch F., Crespo M. Co-Culture of Primary CLL Cells with Bone Marrow Mesenchymal Cells, CD40 Ligand and CpG ODN Promotes Proliferation of Chemoresistant CLL Cells Phenotypically Comparable to Those Proliferating In Vivo. Oncotarget. 2014;6:7632–7643. doi: 10.18632/oncotarget.2939. PubMed DOI PMC

Tretter T., Schuler M., Schneller F., Brass U., Esswein M., Aman M.J., Huber C., Peschel C. Direct Cellular Interaction with Activated CD4(+) T Cells Overcomes Hyporesponsiveness of B-Cell Chronic Lymphocytic Leukemia In Vitro. Cell Immunol. 1998;189:41–50. doi: 10.1006/cimm.1998.1360. PubMed DOI

Patten P.E.M., Buggins A.G.S., Richards J., Wotherspoon A., Salisbury J., Mufti G.J., Hamblin T.J., Devereux S. CD38 Expression in Chronic Lymphocytic Leukemia Is Regulated by the Tumor Microenvironment. Blood. 2008;111:5173–5181. doi: 10.1182/blood-2007-08-108605. PubMed DOI

Romano C., De Fanis U., Sellitto A., Dalla Mora L., Chiurazzi F., Giunta R., Rotoli B., Lucivero G. Effects of Preactivated Autologous T Lymphocytes on CD80, CD86 and CD95 Expression by Chronic Lymphocytic Leukemia B Cells. Leuk. Lymphoma. 2003;44:1963–1971. doi: 10.1080/1042819031000111026. PubMed DOI

Pascutti M.F., Jak M., Tromp J.M., Derks I.A.M., Remmerswaal E.B.M., Thijssen R., van Attekum M.H.A., van Bochove G.G., Luijks D.M., Pals S.T., et al. IL-21 and CD40L Signals from Autologous T Cells Can Induce Antigen-Independent Proliferation of CLL Cells. Blood. 2013;122:3010–3019. doi: 10.1182/blood-2012-11-467670. PubMed DOI

Ghia P., Circosta P., Scielzo C., Vallario A., Camporeale A., Granziero L., Caligaris-Cappio F. Chronic Lymphocytic Leukemia. Springer; Berlin/Heidelberg, Germany: 2005. Differential Effects on CLL Cell Survival Exerted by Different Microenvironmental Elements; pp. 135–145. Current Topics in Microbiology and Immunology. PubMed

Jones C.H., Lin T.T., Walsby E.J., Pratt G.E., Fegan C., Baird D.M., Pepper C. In Vitro Co-Culture of CLL-B Cells Reveals Long-Term Survival, Proliferation, and Maintenance of Telomere Length. Blood. 2016;128:350. doi: 10.1182/blood.V128.22.350.350. DOI

Wiesner M., Zentz C., Mayr C., Wimmer R., Hammerschmidt W., Zeidler R., Moosmann A. Conditional Immortalization of Human B Cells by CD40 Ligation. PLoS ONE. 2008;3:e1464. doi: 10.1371/journal.pone.0001464. PubMed DOI PMC

Willimott S., Baou M., Naresh K., Wagner S.D. CD154 Induces a Switch in Pro-Survival Bcl-2 Family Members in Chronic Lymphocytic Leukaemia. Br. J. Haematol. 2007;138:721–732. doi: 10.1111/j.1365-2141.2007.06717.x. PubMed DOI

Brian A.A. Stimulation of B-Cell Proliferation by Membrane-Associated Molecules from Activated T Cells. Proc. Natl. Acad. Sci. USA. 1988;85:564–568. doi: 10.1073/pnas.85.2.564. PubMed DOI PMC

Schleiss C., Ilias W., Tahar O., Güler Y., Miguet L., Mayeur-Rousse C., Mauvieux L., Fornecker L.-M., Toussaint E., Herbrecht R., et al. BCR-Associated Factors Driving Chronic Lymphocytic Leukemia Cells Proliferation Ex Vivo. Sci. Rep. 2019;9:701. doi: 10.1038/s41598-018-36853-8. PubMed DOI PMC

Liebig T.M., Fiedler A., Zoghi S., Shimabukuro-Vornhagen A., von Bergwelt-Baildon M.S. Generation of Human CD40-Activated B Cells. J. Vis. Exp. 2009;32:1373. doi: 10.3791/1373. PubMed DOI PMC

Ghamlouch H., Darwiche W., Hodroge A., Ouled-Haddou H., Dupont S., Singh A.R., Guignant C., Trudel S., Royer B., Gubler B., et al. Factors Involved in CLL Pathogenesis and Cell Survival Are Disrupted by Differentiation of CLL B-Cells into Antibody-Secreting Cells. Oncotarget. 2015;6:18484–18503. doi: 10.18632/oncotarget.3941. PubMed DOI PMC

Grdisa M. Influence of CD40 Ligation on Survival and Apoptosis of B-CLL Cells In Vitro. Leuk. Res. 2003;27:951–956. doi: 10.1016/S0145-2126(03)00028-6. PubMed DOI

Gricks C.S., Zahrieh D., Zauls A.J., Gorgun G., Drandi D., Mauerer K., Neuberg D., Gribben J.G. Differential Regulation of Gene Expression Following CD40 Activation of Leukemic Compared to Healthy B Cells. Blood. 2004;104:4002–4009. doi: 10.1182/blood-2004-02-0494. PubMed DOI

Scielzo C., Apollonio B., Scarfò L., Janus A., Muzio M., ten Hacken E., Ghia P., Caligaris-Cappio F. The Functional in Vitro Response to CD40 Ligation Reflects a Different Clinical Outcome in Patients with Chronic Lymphocytic Leukemia. Leukemia. 2011;25:1760–1767. doi: 10.1038/leu.2011.149. PubMed DOI

Jacob A., Pound J.D., Challa A., Gordon J. Release of Clonal Block in B Cell Chronic Lymphocytic Leukaemia by Engagement of Co-Operative Epitopes on CD40. Leuk. Res. 1998;22:379–382. doi: 10.1016/S0145-2126(98)00005-8. PubMed DOI

Néron S., Nadeau P.J., Darveau A., Leblanc J.-F. Tuning of CD40-CD154 Interactions in Human B-Lymphocyte Activation: A Broad Array of in Vitro Models for a Complex In Vivo Situation. Arch. Immunol. Ther. Exp. 2011;59:25–40. doi: 10.1007/s00005-010-0108-8. PubMed DOI

Granziero L., Ghia P., Circosta P., Gottardi D., Strola G., Geuna M., Montagna L., Piccoli P., Chilosi M., Caligaris-Cappio F. Survivin Is Expressed on CD40 Stimulation and Interfaces Proliferation and Apoptosis in B-Cell Chronic Lymphocytic Leukemia. Blood. 2001;97:2777–2783. doi: 10.1182/blood.V97.9.2777. PubMed DOI

Néron S., Racine C., Roy A., Guérin M. Differential Responses of Human B-Lymphocyte Subpopulations to Graded Levels of CD40-CD154 Interaction. Immunology. 2005;116:454–463. doi: 10.1111/j.1365-2567.2005.02244.x. PubMed DOI PMC

Dancescu M., Rubio-Trujillo M., Biron G., Bron D., Delespesse G., Sarfati M. Interleukin 4 Protects Chronic Lymphocytic Leukemic B Cells from Death by Apoptosis and Upregulates Bcl-2 Expression. J. Exp. Med. 1992;176:1319–1326. doi: 10.1084/jem.176.5.1319. PubMed DOI PMC

Aguilar-Hernandez M.M., Blunt M.D., Dobson R., Yeomans A., Thirdborough S., Larrayoz M., Smith L.D., Linley A., Strefford J.C., Davies A., et al. IL-4 Enhances Expression and Function of Surface IgM in CLL Cells. Blood. 2016;127:3015–3025. doi: 10.1182/blood-2015-11-682906. PubMed DOI

Guo B., Zhang L., Chiorazzi N., Rothstein T.L. IL-4 Rescues Surface IgM Expression in Chronic Lymphocytic Leukemia. Blood. 2016;128:553–562. doi: 10.1182/blood-2015-11-682997. PubMed DOI PMC

Sandova V., Pavlasova G.M., Seda V., Cerna K.A., Sharma S., Palusova V., Brychtova Y., Pospisilova S., Fernandes S.M., Panovska A., et al. IL4-STAT6 Signaling Induces CD20 in Chronic Lymphocytic Leukemia and This Axis Is Repressed by PI3Kδ Inhibitor Idelalisib. Haematologica. 2021;106:2995–2999. doi: 10.3324/haematol.2021.278644. PubMed DOI PMC

Van Kooten C., Rensink I., Aarden L., van Oers R. Differentiation of Purified Malignant B Cells Induced by PMA or by Activated Normal T Cells. Leukemia. 1993;7:1576–1584. PubMed

Hamilton E., Pearce L., Morgan L., Robinson S., Ware V., Brennan P., Thomas N.S.B., Yallop D., Devereux S., Fegan C., et al. Mimicking the Tumour Microenvironment: Three Different Co-Culture Systems Induce a Similar Phenotype but Distinct Proliferative Signals in Primary Chronic Lymphocytic Leukaemia Cells. Br. J. Haematol. 2012;158:589–599. doi: 10.1111/j.1365-2141.2012.09191.x. PubMed DOI

Tromp J., Tonino S., Elias J., Jaspers A., Luijks D.M., Kater A., Lier R.V., Oers M., Eldering E. Dichotomy in NF-ΚB Signaling and Chemoresistance in Immunoglobulin Variable Heavy-Chain-Mutated versus Unmutated CLL Cells upon CD40/TLR9 Triggering. Oncogene. 2010;29:5071–5082. doi: 10.1038/onc.2010.248. PubMed DOI

Plander M., Seegers S., Ugocsai P., Diermeier-Daucher S., Iványi J., Schmitz G., Hofstädter F., Schwarz S., Orsó E., Knüchel R., et al. Different Proliferative and Survival Capacity of CLL-Cells in a Newly Established in Vitro Model for Pseudofollicles. Leukemia. 2009;23:2118–2128. doi: 10.1038/leu.2009.145. PubMed DOI

Primo D., Scarfò L., Xochelli A., Mattsson M., Ranghetti P., Espinosa A.B., Robles A., Gorrochategui J., Martínez-López J., de la Serna J., et al. A Novel Ex Vivo High-Throughput Assay Reveals Antiproliferative Effects of Idelalisib and Ibrutinib in Chronic Lymphocytic Leukemia. Oncotarget. 2018;9:26019–26031. doi: 10.18632/oncotarget.25419. PubMed DOI PMC

Lu P., Wang S., Franzen C.A., Venkataraman G., McClure R., Li L., Wu W., Niu N., Sukhanova M., Pei J., et al. Ibrutinib and Venetoclax Target Distinct Subpopulations of CLL Cells: Implication for Residual Disease Eradication. Blood Cancer J. 2021;11:1–14. doi: 10.1038/s41408-021-00429-z. PubMed DOI PMC

Mongini P.K.A., Gupta R., Boyle E., Nieto J., Lee H., Stein J., Bandovic J., Stankovic T., Barrientos J., Kolitz J.E., et al. TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells. J. Immunol. 2015;195:901–923. doi: 10.4049/jimmunol.1403189. PubMed DOI PMC

De Totero D., Capaia M., Fabbi M., Croce M., Meazza R., Cutrona G., Zupo S., Loiacono F., Truini M., Ferrarini M., et al. Heterogeneous Expression and Function of IL-21R and Susceptibility to IL-21−mediated Apoptosis in Follicular Lymphoma Cells. Exp. Hematol. 2010;38:373–383. doi: 10.1016/j.exphem.2010.02.008. PubMed DOI

Cecco L.D., Capaia M., Zupo S., Cutrona G., Matis S., Brizzolara A., Orengo A.M., Croce M., Marchesi E., Ferrarini M., et al. Interleukin 21 Controls MRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells. PLoS ONE. 2015;10:e0134706. doi: 10.1371/journal.pone.0134706. PubMed DOI PMC

Chapman E.A., Oates M., Mohammad I.S., Davies B.R., Stockman P.K., Zhuang J., Pettitt A.R. Delineating the Distinct Role of AKT in Mediating Cell Survival and Proliferation Induced by CD154 and IL-4/IL-21 in Chronic Lymphocytic Leukemia. Oncotarget. 2017;8:102948–102964. doi: 10.18632/oncotarget.22292. PubMed DOI PMC

De Totero D., Meazza R., Zupo S., Cutrona G., Matis S., Colombo M., Balleari E., Pierri I., Fabbi M., Capaia M., et al. Interleukin-21 Receptor (IL-21R) Is Up-Regulated by CD40 Triggering and Mediates Proapoptotic Signals in Chronic Lymphocytic Leukemia B Cells. Blood. 2006;107:3708–3715. doi: 10.1182/blood-2005-09-3535. PubMed DOI

Nojima T., Haniuda K., Moutai T., Matsudaira M., Mizokawa S., Shiratori I., Azuma T., Kitamura D. In-Vitro Derived Germinal Centre B Cells Differentially Generate Memory B or Plasma Cells In Vivo. Nat. Commun. 2011;2:465. doi: 10.1038/ncomms1475. PubMed DOI

Caeser R., Di Re M., Krupka J.A., Gao J., Lara-Chica M., Dias J.M.L., Cooke S.L., Fenner R., Usheva Z., Runge H.F.P., et al. Genetic Modification of Primary Human B Cells to Model High-Grade Lymphoma. Nat. Commun. 2019;10:4543. doi: 10.1038/s41467-019-12494-x. PubMed DOI PMC

Buschle M., Campana D., Carding S.R., Richard C., Hoffbrand A.V., Brenner M.K. Interferon Gamma Inhibits Apoptotic Cell Death in B Cell Chronic Lymphocytic Leukemia. J. Exp. Med. 1993;177:213–218. doi: 10.1084/jem.177.1.213. PubMed DOI PMC

Xia M., Luo T.Y., Shi Y., Wang G., Tsui H., Harari D., Spaner D.E. Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells. J. Immunol. 2020;205:2629–2639. doi: 10.4049/jimmunol.2000478. PubMed DOI

Bauvois B., Pramil E., Jondreville L., Quiney C., Nguyen-Khac F., Susin S.A. Activation of Interferon Signaling in Chronic Lymphocytic Leukemia Cells Contributes to Apoptosis Resistance via a JAK-Src/STAT3/Mcl-1 Signaling Pathway. Biomedicines. 2021;9:188. doi: 10.3390/biomedicines9020188. PubMed DOI PMC

Chaouchi N., Wallon C., Goujard C., Tertian G., Rudent A., Caput D., Ferrera P., Minty A., Vazquez A., Delfraissy J.F. Interleukin-13 Inhibits Interleukin-2-Induced Proliferation and Protects Chronic Lymphocytic Leukemia B Cells from In Vitro Apoptosis. Blood. 1996;87:1022–1029. doi: 10.1182/blood.V87.3.1022.bloodjournal8731022. PubMed DOI

Zhu F., McCaw L., Spaner D.E., Gorczynski R.M. Targeting the IL-17/IL-6 Axis Can Alter Growth of Chronic Lymphocytic Leukemia in Vivo/in Vitro. Leuk. Res. 2018;66:28–38. doi: 10.1016/j.leukres.2018.01.006. PubMed DOI

Ghamlouch H., Ouled-Haddou H., Damaj G., Royer B., Gubler B., Marolleau J.-P. A Combination of Cytokines Rescues Highly Purified Leukemic CLL B-Cells from Spontaneous Apoptosis In Vitro. PLoS ONE. 2013;8:e60370. doi: 10.1371/journal.pone.0060370. PubMed DOI PMC

Alhakeem S.S., McKenna M.K., Oben K.Z., Noothi S.K., Rivas J.R., Hildebrandt G.C., Fleischman R.A., Rangnekar V.M., Muthusamy N., Bondada S. Chronic Lymphocytic Leukemia–Derived IL-10 Suppresses Antitumor Immunity. J. Immunol. 2018;200:4180–4189. doi: 10.4049/jimmunol.1800241. PubMed DOI PMC

Slinger E., Thijssen R., Kater A.P., Eldering E. Targeting Antigen-Independent Proliferation in Chronic Lymphocytic Leukemia through Differential Kinase Inhibition. Leukemia. 2017;31:2601–2607. doi: 10.1038/leu.2017.129. PubMed DOI

Fluckiger A.C., Rossi J.F., Bussel A., Bryon P., Banchereau J., Defrance T. Responsiveness of Chronic Lymphocytic Leukemia B Cells Activated via Surface Igs or CD40 to B-Cell Tropic Factors. Blood. 1992;80:3173–3181. doi: 10.1182/blood.V80.12.3173.3173. PubMed DOI

Kater A.P., Evers L.M., Remmerswaal E.B.M., Jaspers A., Oosterwijk M.F., van Lier R.A.W., van Oers M.H.J., Eldering E. CD40 Stimulation of B-Cell Chronic Lymphocytic Leukaemia Cells Enhances the Anti-Apoptotic Profile, but Also Bid Expression and Cells Remain Susceptible to Autologous Cytotoxic T-Lymphocyte Attack. Br. J. Haematol. 2004;127:404–415. doi: 10.1111/j.1365-2141.2004.05225.x. PubMed DOI

Purroy N., Abrisqueta P., Carabia J., Carpio C., Calpe E., Palacio C., Castellví J., Crespo M., Bosch F. Targeting the Proliferative and Chemoresistant Compartment in Chronic Lymphocytic Leukemia by Inhibiting Survivin Protein. Leukemia. 2014;28:1993–2004. doi: 10.1038/leu.2014.96. PubMed DOI

Purroy N., Carabia J., Abrisqueta P., Egia L., Aguiló M., Carpio C., Palacio C., Crespo M., Bosch F. Inhibition of BCR Signaling Using the Syk Inhibitor TAK-659 Prevents Stroma-Mediated Signaling in Chronic Lymphocytic Leukemia Cells. Oncotarget. 2017;8:742–756. doi: 10.18632/oncotarget.13557. PubMed DOI PMC

Ghalamfarsa G., Jadidi-Niaragh F., Hojjat-Farsangi M., Asgarian-Omran H., Yousefi M., Tahmasebi F., Khoshnoodi J., Razavi S.M., Saboor-Yaraghi A.A., Rabbani H., et al. Differential Regulation of B-Cell Proliferation by IL21 in Different Subsets of Chronic Lymphocytic Leukemia. Cytokine. 2013;62:439–445. doi: 10.1016/j.cyto.2013.03.023. PubMed DOI

Ghamlouch H., Ouled-Haddou H., Guyart A., Regnier A., Trudel S., Claisse J.-F., Fuentes V., Royer B., Marolleau J.-P., Gubler B. TLR9 Ligand (CpG Oligodeoxynucleotide) Induces CLL B-Cells to Differentiate into CD20+ Antibody-Secreting Cells. Front. Immunol. 2014;5:292. doi: 10.3389/fimmu.2014.00292. PubMed DOI PMC

Hallaert D.Y.H., Jaspers A., van Noesel C.J., van Oers M.H.J., Kater A.P., Eldering E. C-Abl Kinase Inhibitors Overcome CD40-Mediated Drug Resistance in CLL: Implications for Therapeutic Targeting of Chemoresistant Niches. Blood. 2008;112:5141–5149. doi: 10.1182/blood-2008-03-146704. PubMed DOI

Oppermann S., Ylanko J., Shi Y., Hariharan S., Oakes C.C., Brauer P.M., Zúñiga-Pflücker J.C., Leber B., Spaner D.E., Andrews D.W. High-Content Screening Identifies Kinase Inhibitors That Overcome Venetoclax Resistance in Activated CLL Cells. Blood. 2016;128:934–947. doi: 10.1182/blood-2015-12-687814. PubMed DOI PMC

Hayden R.E., Pratt G., Davies N.J., Khanim F.L., Birtwistle J., Delgado J., Pearce C., Sant T., Drayson M.T., Bunce C.M. Treatment of Primary CLL Cells with Bezafibrate and Medroxyprogesterone Acetate Induces Apoptosis and Represses the Pro-Proliferative Signal of CD40-Ligand, in Part through Increased 15dDelta12,14,PGJ2. Leukemia. 2009;23:292–304. doi: 10.1038/leu.2008.283. PubMed DOI

Hallaert D.Y.H., Spijker R., Jak M., Derks I.a.M., Alves N.L., Wensveen F.M., de Boer J.P., de Jong D., Green S.R., van Oers M.H.J., et al. Crosstalk among Bcl-2 Family Members in B-CLL: Seliciclib Acts via the Mcl-1/Noxa Axis and Gradual Exhaustion of Bcl-2 Protection. Cell Death Differ. 2007;14:1958–1967. doi: 10.1038/sj.cdd.4402211. PubMed DOI

Vogler M., Butterworth M., Majid A., Walewska R.J., Sun X.-M., Dyer M.J.S., Cohen G.M. Concurrent Up-Regulation of BCL-XL and BCL2A1 Induces Approximately 1000-Fold Resistance to ABT-737 in Chronic Lymphocytic Leukemia. Blood. 2009;113:4403–4413. doi: 10.1182/blood-2008-08-173310. PubMed DOI

Thijssen R., Geest C.R., de Rooij M.F., Liu N., Florea B.I., Weller K., Overkleeft H.S., Van Oers M.H.J., Spaargaren M., Kater A.P., et al. Possible Mechanisms Of Resistance To The Novel BH3-Mimetic ABT-199 In In Vitro Lymph Node Models of CLL—The Role of Abl and Btk. Blood. 2013;122:4188. doi: 10.1182/blood.V122.21.4188.4188. DOI

Elias E.E., Sarapura Martinez V.J., Amondarain M., Colado A., Cordini G., Bezares R.F., Fernandez Grecco H., del Rosario Custidiano M., Sánchez Ávalos J.C., Garate G., et al. Venetoclax-Resistant CLL Cells Show a Highly Activated and Proliferative Phenotype. Cancer Immunol. Immunother. 2022;71:979–987. doi: 10.1007/s00262-021-03043-x. PubMed DOI PMC

Jak M., van Bochove G.G.W., van Lier R.a.W., Eldering E., van Oers M.H.J. CD40 Stimulation Sensitizes CLL Cells to Rituximab-Induced Cell Death. Leukemia. 2011;25:968–978. doi: 10.1038/leu.2011.39. PubMed DOI

Jak M., van Bochove G.G.W., Reits E.A., Kallemeijn W.W., Tromp J.M., Umana P., Klein C., van Lier R.A.W., van Oers M.H.J., Eldering E. CD40 Stimulation Sensitizes CLL Cells to Lysosomal Cell Death Induction by Type II Anti-CD20 MAb GA101. Blood. 2011;118:5178–5188. doi: 10.1182/blood-2011-01-331702. PubMed DOI

Blunt M.D., Koehrer S., Dobson R.C., Larrayoz M., Wilmore S., Hayman A., Parnell J., Smith L.D., Davies A., Johnson P.W.M., et al. The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-Cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clin. Cancer Res. 2017;23:2313–2324. doi: 10.1158/1078-0432.CCR-16-1662. PubMed DOI PMC

Crassini K., Shen Y., Stevenson W.S., Christopherson R., Ward C., Mulligan S.P., Best O.G. MEK1/2 Inhibition by Binimetinib Is Effective as a Single Agent and Potentiates the Actions of Venetoclax and ABT-737 under Conditions That Mimic the Chronic Lymphocytic Leukaemia (CLL) Tumour Microenvironment. Br. J. Haematol. 2018;182:360–372. doi: 10.1111/bjh.15282. PubMed DOI

Shen Y., Crassini K., Fatima N., O’Dwyer M., O’Neill M., Christopherson R.I., Mulligan S.P., Best O.G. IBL-202 Is Synergistic with Venetoclax in CLL under in Vitro Conditions That Mimic the Tumor Microenvironment. Blood Adv. 2020;4:5093–5106. doi: 10.1182/bloodadvances.2019001369. PubMed DOI PMC

Kurtova A.V., Balakrishnan K., Chen R., Ding W., Schnabl S., Quiroga M.P., Sivina M., Wierda W.G., Estrov Z., Keating M.J., et al. Diverse Marrow Stromal Cells Protect CLL Cells from Spontaneous and Drug-Induced Apoptosis: Development of a Reliable and Reproducible System to Assess Stromal Cell Adhesion-Mediated Drug Resistance. Blood. 2009;114:4441–4450. doi: 10.1182/blood-2009-07-233718. PubMed DOI PMC

Trimarco V., Ave E., Facco M., Chiodin G., Frezzato F., Martini V., Gattazzo C., Lessi F., Giorgi C.A., Visentin A., et al. Cross-Talk between Chronic Lymphocytic Leukemia (CLL) Tumor B Cells and Mesenchymal Stromal Cells (MSCs): Implications for Neoplastic Cell Survival. Oncotarget. 2015;6:42130–42149. doi: 10.18632/oncotarget.6239. PubMed DOI PMC

Haselager M., Thijssen R., West C., Young L., Van Kampen R., Willmore E., Mackay S., Kater A., Eldering E. Regulation of Bcl-XL by Non-Canonical NF-ΚB in the Context of CD40-Induced Drug Resistance in CLL. Cell Death Differ. 2021;28:1658–1668. doi: 10.1038/s41418-020-00692-w. PubMed DOI PMC

Tromp J.M., Geest C.R., Breij E.C.W., Elias J.A., van Laar J., Luijks D.M., Kater A.P., Beaumont T., van Oers M.H.J., Eldering E. Tipping the Noxa/Mcl-1 Balance Overcomes ABT-737 Resistance in Chronic Lymphocytic Leukemia. Clin. Cancer Res. 2012;18:487–498. doi: 10.1158/1078-0432.CCR-11-1440. PubMed DOI

Elías E.E., Almejún M.B., Colado A., Cordini G., Vergara-Rubio M., Podaza E., Risnik D., Cabrejo M., Fernández-Grecco H., Bezares R.F., et al. Autologous T-Cell Activation Fosters ABT-199 Resistance in Chronic Lymphocytic Leukemia: Rationale for a Combined Therapy with SYK Inhibitors and Anti-CD20 Monoclonal Antibodies. Haematologica. 2018;103:e458–e461. doi: 10.3324/haematol.2018.188680. PubMed DOI PMC

Romano M.F., Lamberti A., Tassone P., Alfinito F., Costantini S., Chiurazzi F., Defrance T., Bonelli P., Tuccillo F., Turco M.C., et al. Triggering of CD40 Antigen Inhibits Fludarabine-Induced Apoptosis in B Chronic Lymphocytic Leukemia Cells. Blood. 1998;92:990–995. doi: 10.1182/blood.V92.3.990. PubMed DOI

Kielbassa K. Ibrutinib Treatment in CLL Interrupts CD40 Signaling Capacity and Sensitizes CLL Cells to Venetoclax. Blood. 2021;138:1545. doi: 10.1182/blood-2021-152222. DOI

Shen Y., Best O.G., Mulligan S.P., Christopherson R.I. Ibrutinib and Idelalisib Block Immunophenotypic Changes Associated with the Adhesion and Activation of CLL Cells in the Tumor Microenvironment. Leuk. Lymphoma. 2018;59:1927–1937. doi: 10.1080/10428194.2017.1403598. PubMed DOI

Delgado R., Kielbassa K., ter Burg J., Klein C., Trumpfheller C., de Heer K., Kater A.P., Eldering E. Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia. Cancers. 2021;13:3084. doi: 10.3390/cancers13123084. PubMed DOI PMC

Mraz M., Zent C.S., Church A.K., Jelinek D.F., Wu X., Pospisilova S., Ansell S.M., Novak A.J., Kay N.E., Witzig T.E., et al. Bone Marrow Stromal Cells Protect Lymphoma B-Cells from Rituximab-Induced Apoptosis and Targeting Integrin α-4-β-1 (VLA-4) with Natalizumab Can Overcome This Resistance. Br. J. Haematol. 2011;155:53–64. doi: 10.1111/j.1365-2141.2011.08794.x. PubMed DOI PMC

Buchner M., Baer C., Prinz G., Dierks C., Burger M., Zenz T., Stilgenbauer S., Jumaa H., Veelken H., Zirlik K. Spleen Tyrosine Kinase Inhibition Prevents Chemokine- and Integrin-Mediated Stromal Protective Effects in Chronic Lymphocytic Leukemia. Blood. 2010;115:4497–4506. doi: 10.1182/blood-2009-07-233692. PubMed DOI

Steele A.J., Prentice A.G., Cwynarski K., Hoffbrand A.V., Hart S.M., Lowdell M.W., Samuel E.R., Wickremasinghe R.G. The JAK3-Selective Inhibitor PF-956980 Reverses the Resistance to Cytotoxic Agents Induced by Interleukin-4 Treatment of Chronic Lymphocytic Leukemia Cells: Potential for Reversal of Cytoprotection by the Microenvironment. Blood. 2010;116:4569–4577. doi: 10.1182/blood-2009-09-245811. PubMed DOI

Ondrisova L., Mraz M. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. Front. Oncol. 2020;10:591577. doi: 10.3389/fonc.2020.591577. PubMed DOI PMC

Gowda A., Roda J., Hussain S.-R.A., Ramanunni A., Joshi T., Schmidt S., Zhang X., Lehman A., Jarjoura D., Carson W.E., et al. IL-21 Mediates Apoptosis through up-Regulation of the BH3 Family Member BIM and Enhances Both Direct and Antibody-Dependent Cellular Cytotoxicity in Primary Chronic Lymphocytic Leukemia Cells In Vitro. Blood. 2008;111:4723–4730. doi: 10.1182/blood-2007-07-099531. PubMed DOI PMC

Ramsay A.G., Clear A.J., Fatah R., Gribben J.G. Multiple Inhibitory Ligands Induce Impaired T-Cell Immunologic Synapse Function in Chronic Lymphocytic Leukemia That Can Be Blocked with Lenalidomide: Establishing a Reversible Immune Evasion Mechanism in Human Cancer. Blood. 2012;120:1412–1421. doi: 10.1182/blood-2012-02-411678. PubMed DOI PMC

Browning R.L., Byrd W.H., Gupta N., Jones J., Mo X., Hertlein E., Yu L., Muthusamy N., Byrd J.C. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. Cancer Immunol. Res. 2016;4:698–707. doi: 10.1158/2326-6066.CIR-15-0291. PubMed DOI PMC

Fanale M., Assouline S., Kuruvilla J., Solal-Céligny P., Heo D.S., Verhoef G., Corradini P., Abramson J.S., Offner F., Engert A., et al. Phase IA/II, Multicentre, Open-Label Study of the CD40 Antagonistic Monoclonal Antibody Lucatumumab in Adult Patients with Advanced Non-Hodgkin or Hodgkin Lymphoma. Br. J. Haematol. 2014;164:258–265. doi: 10.1111/bjh.12630. PubMed DOI PMC

Scielzo C., Ghia P. Modeling the Leukemia Microenviroment In Vitro. Front. Oncol. 2020;10:607608. doi: 10.3389/fonc.2020.607608. PubMed DOI PMC

Abarrategi A., Mian S.A., Passaro D., Rouault-Pierre K., Grey W., Bonnet D. Modeling the Human Bone Marrow Niche in Mice: From Host Bone Marrow Engraftment to Bioengineering Approaches. J. Exp. Med. 2018;215:729–743. doi: 10.1084/jem.20172139. PubMed DOI PMC

Antonelli A., Noort W.A., Jaques J., de Boer B., de Jong-Korlaar R., Brouwers-Vos A.Z., Lubbers-Aalders L., van Velzen J.F., Bloem A.C., Yuan H., et al. Establishing Human Leukemia Xenograft Mouse Models by Implanting Human Bone Marrow–like Scaffold-Based Niches. Blood. 2016;128:2949–2959. doi: 10.1182/blood-2016-05-719021. PubMed DOI

Shah S.B., Singh A. Creating Artificial Lymphoid Tissues to Study Immunity and Hematological Malignancies. Curr. Opin. Hematol. 2017;24:377–383. doi: 10.1097/MOH.0000000000000356. PubMed DOI PMC

Tavakol D.N., Tratwal J., Bonini F., Genta M., Campos V., Burch P., Hoehnel S., Béduer A., Alessandrini M., Naveiras O., et al. Injectable, Scalable 3D Tissue-Engineered Model of Marrow Hematopoiesis. Biomaterials. 2020;232:119665. doi: 10.1016/j.biomaterials.2019.119665. PubMed DOI

Bello A.B., Park H., Lee S.-H. Current Approaches in Biomaterial-Based Hematopoietic Stem Cell Niches. Acta Biomater. 2018;72:1–15. doi: 10.1016/j.actbio.2018.03.028. PubMed DOI

Sbrana F.V., Pinos R., Barbaglio F., Ribezzi D., Scagnoli F., Scarfò L., Redwan I.N., Martinez H., Farè S., Ghia P., et al. 3D Bioprinting Allows the Establishment of Long-Term 3D Culture Model for Chronic Lymphocytic Leukemia Cells. Front. Immunol. 2021;12:639572. doi: 10.3389/fimmu.2021.639572. PubMed DOI PMC

Svozilová H., Plichta Z., Proks V., Studená R., Baloun J., Doubek M., Pospíšilová Š., Horák D. RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model. Int. J. Mol. Sci. 2021;22:2376. doi: 10.3390/ijms22052376. PubMed DOI PMC

Roh K.-H., Song H.W., Pradhan P., Bai K., Bohannon C.D., Dale G., Leleux J., Jacob J., Roy K. A Synthetic Stroma-Free Germinal Center Niche for Efficient Generation of Humoral Immunity Ex Vivo. Biomaterials. 2018;164:106–120. doi: 10.1016/j.biomaterials.2018.02.039. PubMed DOI

Purwada A., Singh A. Immuno-Engineered Organoids for Regulating the Kinetics of B-Cell Development and Antibody Production. Nat. Protoc. 2017;12:168–182. doi: 10.1038/nprot.2016.157. PubMed DOI PMC

Walsby E., Buggins A., Devereux S., Jones C., Pratt G., Brennan P., Fegan C., Pepper C. Development and Characterization of a Physiologically Relevant Model of Lymphocyte Migration in Chronic Lymphocytic Leukemia. Blood. 2014;123:3607–3617. doi: 10.1182/blood-2013-12-544569. PubMed DOI

Pasikowska M., Walsby E., Apollonio B., Cuthill K., Phillips E., Coulter E., Longhi M.S., Ma Y., Yallop D., Barber L.D., et al. Phenotype and Immune Function of Lymph Node and Peripheral Blood CLL Cells Are Linked to Transendothelial Migration. Blood. 2016;128:563–573. doi: 10.1182/blood-2016-01-683128. PubMed DOI

Barbaglio F., Belloni D., Scarfò L., Sbrana F.V., Ponzoni M., Bongiovanni L., Pavesi L., Zambroni D., Stamatopoulos K., Caiolfa V.R., et al. Three-Dimensional Co-Culture Model of Chronic Lymphocytic Leukemia Bone Marrow Microenvironment Predicts Patient-Specific Response to Mobilizing Agents. Haematologica. 2021;106:2334–2344. doi: 10.3324/haematol.2020.248112. PubMed DOI PMC

Lamaison C., Latour S., Hélaine N., Le Morvan V., Saint-Vanne J., Mahouche I., Monvoisin C., Dussert C., Andrique L., Deleurme L., et al. A Novel 3D Culture Model Recapitulates Primary FL B-Cell Features and Promotes Their Survival. Blood Adv. 2021;5:5372–5386. doi: 10.1182/bloodadvances.2020003949. PubMed DOI PMC

Simonetti G., Bertilaccio M.T.S., Ghia P., Klein U. Mouse Models in the Study of Chronic Lymphocytic Leukemia Pathogenesis and Therapy. Blood. 2014;124:1010–1019. doi: 10.1182/blood-2014-05-577122. PubMed DOI

Bresin A., D’Abundo L., Narducci M.G., Fiorenza M.T., Croce C.M., Negrini M., Russo G. TCL1 Transgenic Mouse Model as a Tool for the Study of Therapeutic Targets and Microenvironment in Human B-Cell Chronic Lymphocytic Leukemia. Cell Death Dis. 2016;7:e2071. doi: 10.1038/cddis.2015.419. PubMed DOI PMC

Bichi R., Shinton S.A., Martin E.S., Koval A., Calin G.A., Cesari R., Russo G., Hardy R.R., Croce C.M. Human Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted TCL1 Expression. Proc. Natl. Acad. Sci. USA. 2002;99:6955–6960. doi: 10.1073/pnas.102181599. PubMed DOI PMC

Gorgun G., Ramsay A.G., Holderried T.A.W., Zahrieh D., Le Dieu R., Liu F., Quackenbush J., Croce C.M., Gribben J.G. Eµ-TCL1 Mice Represent a Model for Immunotherapeutic Reversal of Chronic Lymphocytic Leukemia-Induced T-Cell Dysfunction. Proc. Natl. Acad. Sci. USA. 2009;106:6250–6255. doi: 10.1073/pnas.0901166106. PubMed DOI PMC

Hofbauer J.P., Heyder C., Denk U., Kocher T., Holler C., Trapin D., Asslaber D., Tinhofer I., Greil R., Egle A. Development of CLL in the TCL1 Transgenic Mouse Model Is Associated with Severe Skewing of the T-Cell Compartment Homologous to Human CLL. Leukemia. 2011;25:1452–1458. doi: 10.1038/leu.2011.111. PubMed DOI

Kocher T., Asslaber D., Zaborsky N., Flenady S., Denk U., Reinthaler P., Ablinger M., Geisberger R., Bauer J.W., Seiffert M., et al. CD4+ T Cells, but Not Non-Classical Monocytes, Are Dispensable for the Development of Chronic Lymphocytic Leukemia in the TCL1-Tg Murine Model. Leukemia. 2016;30:1409–1413. doi: 10.1038/leu.2015.307. PubMed DOI PMC

Grioni M., Brevi A., Cattaneo E., Rovida A., Bordini J., Bertilaccio M.T.S., Ponzoni M., Casorati G., Dellabona P., Ghia P., et al. CD4+ T Cells Sustain Aggressive Chronic Lymphocytic Leukemia in Eμ-TCL1 Mice through a CD40L-Independent Mechanism. Blood Adv. 2021;5:2817–2828. doi: 10.1182/bloodadvances.2020003795. PubMed DOI PMC

Zapata J.M., Krajewska M., Morse H.C., Choi Y., Reed J.C. TNF Receptor-Associated Factor (TRAF) Domain and Bcl-2 Cooperate to Induce Small B Cell Lymphoma/Chronic Lymphocytic Leukemia in Transgenic Mice. Proc. Natl. Acad. Sci. USA. 2004;101:16600–16605. doi: 10.1073/pnas.0407541101. PubMed DOI PMC

Munzert G., Kirchner D., Stobbe H., Bergmann L., Schmid R.M., Döhner H., Heimpel H. Tumor Necrosis Factor Receptor-Associated Factor 1 Gene Overexpression in B-Cell Chronic Lymphocytic Leukemia: Analysis of NF-ΚB/Rel–Regulated Inhibitors of Apoptosis. Blood. 2002;100:3749–3756. doi: 10.1182/blood.V100.10.3749. PubMed DOI

Elgueta R., Benson M.J., de Vries V.C., Wasiuk A., Guo Y., Noelle R.J. Molecular Mechanism and Function of CD40/CD40L Engagement in the Immune System. Immunol. Rev. 2009;229:152–172. doi: 10.1111/j.1600-065X.2009.00782.x. PubMed DOI PMC

Lee S.Y., Reichlin A., Santana A., Sokol K.A., Nussenzweig M.C., Choi Y. TRAF2 Is Essential for JNK but Not NF-KappaB Activation and Regulates Lymphocyte Proliferation and Survival. Immunity. 1997;7:703–713. doi: 10.1016/S1074-7613(00)80390-8. PubMed DOI

Shimoni A., Marcus H., Canaan A., Ergas D., David M., Berrebi A., Reisner Y. A Model for Human B-Chronic Lymphocytic Leukemia in Human/Mouse Radiation Chimera: Evidence for Tumor-Mediated Suppression of Antibody Production in Low-Stage Disease. Blood. 1997;89:2210–2218. doi: 10.1182/blood.V89.6.2210. PubMed DOI

Shimoni A., Marcus H., Dekel B., Shkarchi R., Arditti F., Shvidel L., Shtalrid M., Bucher W., Canaan A., Ergas D., et al. Autologous T Cells Control B-Chronic Lymphocytic Leukemia Tumor Progression in Human→Mouse Radiation Chimera. Cancer Res. 1999;59:5968–5974. PubMed

Dürig J., Ebeling P., Grabellus F., Sorg U.R., Möllmann M., Schütt P., Göthert J., Sellmann L., Seeber S., Flasshove M., et al. A Novel Nonobese Diabetic/Severe Combined Immunodeficient Xenograft Model for Chronic Lymphocytic Leukemia Reflects Important Clinical Characteristics of the Disease. Cancer Res. 2007;67:8653–8661. doi: 10.1158/0008-5472.CAN-07-1198. PubMed DOI

Aydin S., Grabellus F., Eisele L., Möllmann M., Hanoun M., Ebeling P., Moritz T., Carpinteiro A., Nückel H., Sak A., et al. Investigating the Role of CD38 and Functionally Related Molecular Risk Factors in the CLL NOD/SCID Xenograft Model. Eur. J. Haematol. 2011;87:10–19. doi: 10.1111/j.1600-0609.2011.01626.x. PubMed DOI

Bagnara D., Kaufman M.S., Calissano C., Marsilio S., Patten P.E.M., Simone R., Chum P., Yan X.-J., Allen S.L., Kolitz J.E., et al. A Novel Adoptive Transfer Model of Chronic Lymphocytic Leukemia Suggests a Key Role for T Lymphocytes in the Disease. Blood. 2011;117:5463–5472. doi: 10.1182/blood-2010-12-324210. PubMed DOI PMC

Patten P.E.M., Ferrer G., Chen S.-S., Kolitz J.E., Rai K.R., Allen S.L., Barrientos J.C., Ioannou N., Ramsay A.G., Chiorazzi N. A Detailed Analysis of Parameters Supporting the Engraftment and Growth of Chronic Lymphocytic Leukemia Cells in Immune-Deficient Mice. Front. Immunol. 2021;12:627020. doi: 10.3389/fimmu.2021.627020. PubMed DOI PMC

Oldreive C.E., Skowronska A., Davies N.J., Parry H., Agathanggelou A., Krysov S., Packham G., Rudzki Z., Cronin L., Vrzalikova K., et al. T-Cell Number and Subtype Influence the Disease Course of Primary Chronic Lymphocytic Leukaemia Xenografts in Alymphoid Mice. Dis. Models Mech. 2015;8:1401–1412. doi: 10.1242/dmm.021147. PubMed DOI PMC

Decker S., Zwick A., Khaja Saleem S., Kissel S., Rettig A., Aumann K., Dierks C. Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups. Int. J. Mol. Sci. 2019;20:6277. doi: 10.3390/ijms20246277. PubMed DOI PMC

Davies N.J., Kwok M., Gould C., Oldreive C.E., Mao J., Parry H., Smith E., Agathanggelou A., Pratt G., Taylor A.M.R., et al. Dynamic Changes in Clonal Cytogenetic Architecture during Progression of Chronic Lymphocytic Leukemia in Patients and Patient-Derived Murine Xenografts. Oncotarget. 2017;8:44749–44760. doi: 10.18632/oncotarget.17432. PubMed DOI PMC

Herman S.E.M., Sun X., McAuley E.M., Hsieh M.M., Pittaluga S., Raffeld M., Liu D., Keyvanfar K., Chapman C.M., Chen J., et al. Modeling Tumor-Host Interactions of Chronic Lymphocytic Leukemia in Xenografted Mice to Study Tumor Biology and Evaluate Targeted Therapy. Leukemia. 2013;27:2311–2321. doi: 10.1038/leu.2013.131. PubMed DOI PMC

Patten P.E.M., Ferrer G., Chen S.-S., Simone R., Marsilio S., Yan X.-J., Gitto Z., Yuan C., Kolitz J.E., Barrientos J., et al. Chronic Lymphocytic Leukemia Cells Diversify and Differentiate in Vivo via a Nonclassical Th1-Dependent, Bcl-6-Deficient Process. JCI Insight. 2016;1:e86288. doi: 10.1172/jci.insight.86288. PubMed DOI PMC

Nagatani M., Kodera T., Suzuki D., Igura S., Fukunaga Y., Kanemitsu H., Nakamura D., Mochizuki M., Kemi M., Tamura K., et al. Comparison of Biological Features between Severely Immuno-Deficient NOD/Shi-Scid Il2rgnull and NOD/LtSz-Scid Il2rgnull Mice. Exp. Anim. 2019;68:471–482. doi: 10.1538/expanim.19-0024. PubMed DOI PMC

Kikushige Y., Ishikawa F., Miyamoto T., Shima T., Urata S., Yoshimoto G., Mori Y., Iino T., Yamauchi T., Eto T., et al. Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Human Chronic Lymphocytic Leukemia. Cancer Cell. 2011;20:246–259. doi: 10.1016/j.ccr.2011.06.029. PubMed DOI

Burack W.R., Spence J.M., Spence J.P., Spence S.A., Rock P.J., Shenoy G.N., Shultz L.D., Bankert R.B., Bernstein S.H. Patient-Derived Xenografts of Low-Grade B-Cell Lymphomas Demonstrate Roles of the Tumor Microenvironment. Blood Adv. 2017;1:1263–1273. doi: 10.1182/bloodadvances.2017005892. PubMed DOI PMC

In vitro culture of leukemic cells in collagen scaffolds and carboxymethyl cellulose-polyethylene glycol gel

FoxO1/Rictor axis induces a nongenetic adaptation to ibrutinib via Akt activation in chronic lymphocytic leukemia

Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs